Glenmark Pharmaceuticals has received final approval from the U.S. Food and Drug Administration for its Progesterone Vaginal Inserts, 100 mg, marking a meaningful step forward in expanding access to fertility care in the United States.
The product is a generic equivalent of Endometrin and is used for progesterone supplementation, an essential component in assisted reproductive treatments. By supporting embryo implantation and early-stage pregnancy, the therapy plays a key role for patients undergoing fertility procedures.
This approval opens the door for Glenmark to enter a well-established U.S. market with steady demand, while offering a more affordable alternative for patients. It also reflects the company’s continued focus on strengthening its presence in regulated markets and addressing gaps in women’s healthcare.
With a growing portfolio of complex generics and specialty products, Glenmark is steadily advancing its global footprint. The latest approval reinforces its commitment to improving patient access to quality medicines while responding to evolving healthcare needs in critical therapy areas.
